Detalhe da pesquisa
1.
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Oncology
; 102(3): 239-251, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-37729889
2.
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Oncology
; 101(8): 491-501, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37429266
3.
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
BMC Gastroenterol
; 23(1): 222, 2023 Jun 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37380950
4.
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices.
BMC Gastroenterol
; 22(1): 535, 2022 Dec 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36550416
5.
Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study.
BMC Gastroenterol
; 22(1): 275, 2022 Jun 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35655156
6.
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Oncology
; 99(8): 507-517, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33946070
7.
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Oncology
; 99(5): 327-335, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33677453
8.
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Oncology
; 99(8): 491-498, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34000725
9.
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Cancer Med
; 13(5): e7025, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38477514
10.
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Intern Med
; 62(12): 1771-1774, 2023 Jun 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36328580
11.
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions.
Cancers (Basel)
; 15(3)2023 Jan 30.
Artigo
Inglês
| MEDLINE | ID: mdl-36765804
12.
Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.
Yonago Acta Med
; 66(4): 422-431, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38028262
13.
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
Cancers (Basel)
; 15(8)2023 Apr 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37190231
14.
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Liver Cancer
; 12(3): 251-261, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37601981
15.
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 15(22)2023 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38001666
16.
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Case Rep Gastroenterol
; 16(1): 110-115, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35431768
17.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
J Gastroenterol
; 57(9): 676-683, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35849192
18.
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 14(20)2022 Oct 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36291850
19.
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
PLoS One
; 17(1): e0262675, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35041693
20.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 14(2)2022 Jan 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35053484